About Dermatophytic Onychomycosis
Dermatophytic onychomycosis is a fungal infection of the nail plate, nail bed, and, in some cases, the skin surrounding the nail plate. It is caused by yeast, dermatophytes, and molds; dermatophytes account for 90% of all cases. The fungus, especially Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, infects the skin, hair, or nails. It is often perceived by people to be an active and contagious infection. Onychomycosis may persist or worsen if not treated. The fungi that cause onychomycosis exist in common sites such as floors, soil, socks, and shoes. Therapies for onychomycosis include debridement and drugs. Debridement is time consuming and minimally effective in eradicating the fungal infection. Systemic drug treatment is most effective in treating onychomycosis.
Technavio’s analysts forecast the global dermatophytic onychomycosis market to grow at a CAGR of 7.44% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global dermatophytic onychomycosis market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat and prevent onychomycosis.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Dermatophytic Onychomycosis Market 2016-2020
Technavio recognizes the following companies as the key players in the Global Dermatophytic Onychomycosis Market: Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis and Valeant Pharmaceuticals
Other Prominent Vendors in the market are: Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals and Viamet Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “It has been found that a combination of topical and systemic treatment increases the cure rate when compared to individual therapies. For instance, a combination of amorolfine nail lacquer and oral terbinafine, the most commonly used combination therapy, has improved clinical efficiency and is more cost-effective than terbinafine alone. At times, the combination of surgery and systemic and topical therapies are also used. Sometimes, non-pharmacological approaches such as laser or mechanical treatment are also used in combination with topical and systemic therapy. Such trends will have a positive impact on the growth of the market.”
According to the report, the increase in R&D to develop drugs with disease-modifying properties and a better safety and efficacy profile drives the market.
Further, the report states that the side effects associated with dermatophytic onychomycosis drugs are a challenge to the market as they hamper the acceptance of advanced drugs to treat moderate to severe dermatophytic onychomycosis.
Anacor Pharmaceuticals, Galderma, Janssen Biotech, Novartis, Valeant Pharmaceuticals, Abeona Therapeutics, Allergan, Elorac, GlaxoSmithKline, Hexima, Hisamitsu Pharmaceutical, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharma, Moberg Pharma, NanoBio, NovaBiotics, Nuvo Research, Pfizer, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Taro Pharmaceutical, Topica Pharmaceuticals, Viamet Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook